Health ❯ Healthcare ❯ Drug Development

Clinical Research

Phase 3 Trials Patient Enrollment Efficacy Studies AstraZeneca Studies Eli Lilly Lynozyfic Therapeutic Advances Genetic Studies Efficacy and Safety Studies Phase 3 Studies Phase Trials Patient Safety PIPI Drugs Nebulized Therapies Alzheimer's Treatments SpringWorks Therapeutics Experimental Drugs Cancer Risk Regulatory Approval Fabhalta Eli Lilly Trials Povetacicept ALXN1840 WVE-007 Laboratory Practices VK2735 Semaglutide Peptide Inhibitors Phase 2 Trials Pharmaceutical Companies Oncology Alzheimer's Focus Mental Health Treatments GLP-1 Treatments Therapeutics Phase 1 Studies

4 ARTICLES

last mo.

ETH Zurich Pins GRK2 Aggregation as Alzheimer’s Target and Reveals 'Compound 10' That Slows Decline in Mice

Preclinical results show the small molecule prevents GRK2 clumping, restores mitochondrial function and lowers amyloid‑beta while the lab seeks a commercial partner for development.

3 ARTICLES

2mo ago

Legend Biotech Q1 Sales Jump on CARVYKTI Growth Despite Expansion-Related Margin Hit

7 ARTICLES

2mo ago

FDA Delays Two Drugs in National Priority Voucher Program After Safety, Efficacy Flags

5 ARTICLES

6mo ago

Alveus Therapeutics Launches With $159.8 Million Series A to Advance Next‑Generation Obesity Drugs

3 ARTICLES

7mo ago

Nektar’s Alopecia Drug Misses Phase 2b Goal as Company Cites Ineligible Patients, Plans Phase 3

7 ARTICLES

7mo ago

Wave Life Sciences Soars on Obesity Trial Signal as It Begins $250 Million Stock Offering

3 ARTICLES

7mo ago

FDA Grants Breakthrough Therapy Designation to Incyte’s CALR‑Targeting Antibody as ASH Data Show Early Efficacy in Myelofibrosis

3 ARTICLES

7mo ago

Junshi’s Subcutaneous Toripalimab Matches IV in Phase 3 NSCLC Trial as Company Prepares NDA

3 ARTICLES

9mo ago

Novartis’ Fabhalta Slows Kidney Function Decline in Final Phase 3 IgAN Results

6 ARTICLES

9mo ago

Lilly’s Oral GLP-1 Orforglipron Beats Farxiga and Placebo in Two Phase 3 Diabetes Trials

Clinical Research

ETH Zurich Pins GRK2 Aggregation as Alzheimer’s Target and Reveals 'Compound 10' That Slows Decline in Mice

Legend Biotech Q1 Sales Jump on CARVYKTI Growth Despite Expansion-Related Margin Hit

FDA Authorizes Early Access to Daraxonrasib for Pancreatic Cancer Patients

FDA Launches First Real-Time Clinical Trial Pilot With AstraZeneca and Amgen

Karyopharm Raises $30 Million in RA Capital Private Placement

Vertex’s IgA Nephropathy Drug Hits Phase 3 Goals, FDA Filing Slated for March

FDA Delays Two Drugs in National Priority Voucher Program After Safety, Efficacy Flags

Alveus Therapeutics Launches With $159.8 Million Series A to Advance Next‑Generation Obesity Drugs

Nektar’s Alopecia Drug Misses Phase 2b Goal as Company Cites Ineligible Patients, Plans Phase 3

Wave Life Sciences Soars on Obesity Trial Signal as It Begins $250 Million Stock Offering

FDA Grants Breakthrough Therapy Designation to Incyte’s CALR‑Targeting Antibody as ASH Data Show Early Efficacy in Myelofibrosis

Junshi’s Subcutaneous Toripalimab Matches IV in Phase 3 NSCLC Trial as Company Prepares NDA

Novartis’ Fabhalta Slows Kidney Function Decline in Final Phase 3 IgAN Results

Lilly’s Oral GLP-1 Orforglipron Beats Farxiga and Placebo in Two Phase 3 Diabetes Trials